Cancer Guidelines Database

Access quality cancer guidelines from a single Canadian source

We've listed guidelines under your selection of "Continuum of care". The most recent guidelines are first.

European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) Recommendations for the Surgical Management of Adrenocortical Carcinoma

Year: 2017
AGREE II score: Available
Developer organization: European Society of Endocrine Surgeons
This is a clinical practice guideline on the perioperative care of patients undergoing surgery for adrenocortical carcinoma (ACC). Topics covered in the guideline include the optimal preoperative investigations, surgical approach, quality criteria of the operative note and pathological report, follow-up after surgery, surgical management of metastatic and/or recurrent ACC, and debulking or palliative surgery. The guideline also emphasizes the need for inclusion in collaborative and/or prospective databases to advance research and evidence on the topic.

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Year: 2017
AGREE II score: Unavailable
Developer organization: European School of Oncology
This is a clinical practice guideline for the management of patients with advanced breast cancer (ABC), including those with locally advanced breast cancer (LABC) and metastatic breast cancer (MBC). The guideline provides recommendations for the management of these patients, and specifically discusses the use of chemotherapy, management of bone metastases, management of cancer related fatigue, as well as supportive and palliative care.

Endoscopic Surveillance After Surgical or Endoscopic Resection for Colorectal Cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline

Year: 2019
AGREE II score: Available
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
This is a clinical practice guideline for patients who have been operated on for sporadic colorectal cancer (CRC) and for those in whom a low risk T1 CRC has been completely removed at endoscopy. The guideline discusses the endoscopic surveillance of these patients, and provides recommendations on the appropriate timing of endoscopy (i.e. in specific intervals following surgery), and the age at which to halt the use of surveillance endoscopy. Outcomes of interest include overall survival, CRC-specific survival, relapse-free survival, and adverse effects.

Guidelines for Enhanced Recovery After Lung Surgery: Recommendations of the Enhanced Recovery After Surgery (ERAS) Society and the European Society of Thoracic Surgeons (ESTS)

Year: 2018
AGREE II score: Available
Developer organization: Enhanced Recovery After Surgery Group
This is a clinical practice guideline for the optimal preoperative management of patients undergoing thoracic surgery, and primarily, lung resection. Topics covered in the guideline include preoperative counselling, nutritional screening, smoking cessation, prehabilitation for high-risk patients, avoidance of fasting, carbohydrate loading, avoidance of preoperative sedatives, venous thromboembolism prophylaxis, prevention of hypothermia, short-acting anesthetics to facilitate early emergence, regional anesthesia, nausea and vomiting control, opioid-sparing analgesia, euvolemic fluid management, minimally invasive surgery, early chest drain removal, avoidance of urinary catheters and early mobilization after surgery.

The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Year: 2018
AGREE II score: Available
Developer organization: Society for Immunotherapy of Cancer
This is a clinical practice guideline for patients with non-small cell lung cancer (NSCLC). The guideline provides recommendations on the use of immunotherapy as treatment for these patients, using the immune checkpoint inhibitors pembrolizumab, nivolumab and atezolizumab. Specific topics discussed include appropriate patient selection, sequencing of therapies, response monitoring, adverse event management, and biomarker testing.

The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Prostate Carcinoma

Year: 2016
AGREE II score: Available
Developer organization: Society for Immunotherapy of Cancer
This is a clinical practice guideline for patients with prostate cancer. The guideline provides recommendations on the use of immunotherapy for the treatment of these patients, with recommendations separated based on the stage of disease (i.e. whether metastatic or non-metastatic, castration-sensitive or castration-resistant). Specific topics discussed include issues related to patient selection, monitoring of patients during and after treatment, and sequence/combination with other anti-cancer treatments.

Diagnosis of Upper Quadrant Lymphedema Secondary to Cancer: Clinical Practice Guideline From the Oncology Section of the American Physical Therapy Association

Year: 2017
AGREE II score: Available
Developer organization: American Physical Therapy Association
This is a clinical practice guideline for adult patients who have undergone cancer treatment, and are at risk for developing secondary upper quadrant lymphedema (SUQL). The guideline provides recommendations for the diagnosis of SUQL, using methods such as clinical examination and patient-reported symptom assessments, bioimpedance analysis, circumferential measurement, water displacement, and imaging techniques such as magnetic resonance imaging (MRI), and computed tomography (CT). The primary outcomes of interest are decreases in both morbidity as well as activity and participation restrictions, and an increase in overall quality of life (QOL).

Best Practices for the Management of Local-Regional Recurrent Chordoma: A Position Paper by the Chordoma Global Consensus Group

Year: 2017
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for patients who have received initial treatment for chordomas, who are at risk for loco-regional recurrence. The guideline provides recommendations for pre-treatment assessment, resection of recurrent or progressive disease, radiotherapy of recurrence, other local therapies, follow-up, as well as for palliative, supportive and end-of-life care. Outcomes of interest include quality of life, recurrence-free survival, and overall survival.

BGCS Uterine Cancer Guidelines: Recommendations for Practice

Year: 2017
AGREE II score: Unavailable
Developer organization: British Gynaecological Cancer Society
This is a clinical practice guideline for women with uterine cancer. The guideline provides recommendations for the screening and prevention of uterine cancer in the general population and in high risk groups, as well as for the pathological work-up, management, and follow-up of patients with uterine cancer. Specific conditions discussed include endometrioid endometrial cancer, as well as non-endometrioid cancers such as uterine serous carcinoma, uterine clear cell carcinoma, and uterine carcinosarcoma.

British Gynaecological Cancer Society (BGCS) Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: Recommendations for Practice

Year: 2017
AGREE II score: Unavailable
Developer organization: British Gynaecological Cancer Society
This is a clinical practice guideline for patients with epithelial ovarian-type cancers (e.g. ovary, fallopian tube or peritoneal origin) and borderline tumours. This guideline addresses epithelial cancers of varying histological subtypes. The guideline covers the full continuum of care including screening and prevention, diagnosis, treatment options such as surgery, systemic therapy and chemotherapy, follow-up, as well as management of recurrent disease. The guideline also highlights the support needs for women with ovarian cancer.